Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis.

Najjar-Debbiny, Ronza; Gronich, Naomi; Weber, Gabriel; Stein, Nili; Saliba, Walid

Najjar-Debbiny, Ronza; Gronich, Naomi; Weber, Gabriel; Stein, Nili; Saliba, Walid.

Afiliación

Najjar-Debbiny R; Infection Control and Prevention Unit, Lady Davis Carmel Medical Center.
Gronich N; Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology.
Weber G; Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology.
Stein N; Department of Community Medicine and Epidemiology.
Saliba W; Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology.

Clin Infect Dis ; 76(6): 1067-1073, 2023 03 21.

Article en En | MEDLINE | ID: mdl-36310534

Asunto(s)

COVID-19; Adulto; Humanos; SARS-CoV-2; Puntaje de Propensión; Huésped Inmunocomprometido

Palabras clave

COVID-19; Evusheld; SARS-CoV-2; effectiveness; tixagevimab and cilgavimab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Prognostic_studies Límite: Adult / Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google